GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (STU:1IJA) » Definitions » Valuation Rank

Adicet Bio (STU:1IJA) Valuation Rank


View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Adicet Bio Valuation Rank Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Adicet Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (STU:1IJA) » Definitions » Valuation Rank
Comparable Companies
IMAB DOMH EPIX NTRB ACRV CRBP JSPR MNOV ABOS VANI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ACET:USA 0HX7:UK 1IJA:Germany
Address
131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Website
https://www.adicetbio.com
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.